SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
4	Oct 5, 2026	Oct 5, 2026	View filing
4	Oct 5, 2026	Oct 5, 2026	View filing
4	Oct 5, 2026	Oct 5, 2026	View filing
4	Oct 5, 2026	Oct 5, 2026	View filing
3	Oct 5, 2026	Oct 5, 2026	View filing
4	Sep 28, 2026	Sep 28, 2026	View filing
8-K	Sep 23, 2026	Sep 23, 2026	View filing
4	Sep 18, 2026	Sep 18, 2026	View filing
4	Sep 18, 2026	Sep 18, 2026	View filing
4	Sep 16, 2026	Sep 16, 2026	View filing
4	Sep 16, 2026	Sep 16, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
3	Sep 3, 2026	Sep 3, 2026	View filing
4	Aug 28, 2026	Aug 28, 2026	View filing
4	Aug 27, 2026	Aug 27, 2026	View filing
4	Aug 20, 2026	Aug 20, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
4	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G/A	Aug 13, 2026	Aug 13, 2026	View filing
4	Aug 12, 2026	Aug 12, 2026	View filing
4	Aug 12, 2026	Aug 12, 2026	View filing
4	Aug 6, 2026	Aug 6, 2026	View filing
4	Aug 5, 2026	Aug 5, 2026	View filing

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.

Redwood City, CA

730 employees

www.corcept.com

Healthcare / Medical - Pharmaceuticals

Sector: Healthcare
Industry: Medical - Pharmaceuticals
CEO: Joseph K. Belanoff

View full financials